Codexis (CDXS) Insider De Vre Raymond Buys 66,350 Shares
De Vre Raymond bought 66,350 shares of Codexis, Inc. on June 17, 2026, as the stock trades at $2.57.
Reviewed by automated data checks against the source filing. How we make and check alerts
De Vre Raymond bought 66,350 shares of Codexis, Inc. ($CDXS) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDXS is down 8.5% after 1 week, down 9.7% after 1 month and down 50.0% to date (from the $2.48 close on Jun 17, 2026).
CDXS
Codexis, Inc.
Key Points
- On June 17, 2026, De Vre Raymond purchased 66,350 shares of Codexis, Inc. at a price of $2.57 per share.
- Codexis, Inc. has a market cap of approximately $151.1 million and operates in the biotechnology industry.
- Analysts give Codexis a consensus rating of 'buy' with a target price of $8.00, reflecting optimism about its future.
Get $CDXS trade alerts by text
We text you when insiders, Congress or big funds trade $CDXS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Codexis, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Codexis, Inc.
On June 17, 2026, De Vre Raymond bought 66,350 shares of Codexis, Inc. (CDXS) on the NasdaqGS, with the stock trading at $2.57 at the time of the purchase. This move adds to the growing interest in the company, which operates in the biotechnology sector.
Multiple Insiders Make Similar Moves
This buy is part of a larger trend, as several insiders at Codexis also acquired the same number of shares on the same day. Cynthia Collins, Dilly Stephen George, Esther Martinborough, Rahul Singhvi, David Smith, and Stewart Parker each bought 66,350 shares on June 17, 2026. These transactions may indicate strong internal confidence in the company's direction.
How Codexis, Inc. Stock Has Traded
As of the last trading session, Codexis shares are priced at $2.57. The stock has fluctuated between $0.96 and $2.98 over the past year. This recent insider activity comes as the company looks to capitalize on its proprietary technology solutions for therapeutics manufacturing.
Analysts Set New Price Targets
On August 17, 2026, Piper Sandler maintained an 'Overweight' rating on Codexis, with a price target of $8.00, down from a prior target of $9.00. This suggests that analysts are still optimistic about the company's future despite the adjustment in their price target.
What Codexis, Inc. Does
Codexis, Inc. specializes in technology solutions for manufacturing therapeutics. With its proprietary CodeEvolver technology, the company aims to discover and develop novel enzymes for various applications. This insider buying activity could signal a belief in the potential of its innovative solutions.
What to Watch at Codexis, Inc.
Investors should keep an eye on Codexis's upcoming earnings report scheduled for November 5, 2026. The recent insider trades collectively reflect a strong belief in the company's future, and further filings could provide additional insights into its direction.
Related Filing Alerts
Source: De Vre Raymond's Form 4 filing on $CDXS (Jun 17, 2026). Find the original filing: CDXS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts